Altimmune, Inc.

Healthcare · Biotechnology · United States

Last price 2.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 396.82M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.